GÇGülfem Çelik

Gülfem Çelik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gülfem Çelik has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2009
      • Vol. 57  (4) , 439-52

    The WHO global alliance against chronic respiratory diseases in Turkey (GARD Turkey).

    by Arzu Yorgancıoglu, H Türktaş, O Kalayci, Nazan Yardim, T Buzgan, A Kocabaş, C Karlikaya, F Yildiz, P Ergün, D Mungan, et al.

    In order to prevent and control non-communicable diseases (NCDs), the 61st World Health Assembly has endorsed an NCD action plan (WHA resolution 61.14). A package for essential NCDs including chronic respiratory diseases (CRDs) has also been developed. The Global Alliance against Chronic Respiratory Diseases (GARD) is a new but rapidly developing voluntary alliance that is assisting World Health Organization (WHO) in the task of addressing NCDs at country level. The GARD approach was initiated in 2006. GARD Turkey is the first comprehensive programme developed by a government with all stakeholders of the country. This paper provides a summary of indicators of the prevalence and severity of chronic respiratory diseases in Turkey and the formation of GARD Turkey.


    • 1 January 2007
      • Vol. 17  (4) , 242-8

    Dipyrone improves small airway function in asthmatic patients with moderate obstruction.

    by S E Gulmez, G Celik, Z Misirligil, F C Tulunay

    Dipyrone is an analgesic and antipyretic agent with a distinctive spasmolytic effect on smooth muscles. We recently showed that dipyrone significantly relaxed precontracted tracheal smooth muscle in guinea pig. To investigate whether this in vitro observation could be observed in vivo in the respiratory function parameters of asthma patients. Twenty-two patients, aged 18 to 75 years and diagnosed with asthma according to the American Thoracic Society criteria were enrolled at the time they had any indication for dipyrone use. Pulmonary function tests were performed before and 30, 60, 90, and 120 minutes after oral intake of 1 g of dipyrone. The tests were repeated without dipyrone intake in a situation of spontaneous recovery after a minimum washout period of 2 days. Patients were classified according to their baseline forced expiratory volume in 1 second (FEV1) as having mild obstruction (FEV > or =80% predicted) or moderate obstruction (FEV1 60%-80% predicted). Significant improvement with dipyrone was seen in FEV1 and peak expiratory flow rates at 25%, 50% and 75%) of forced vital capacity and in maximum midexpiratory flow rate only in patients with moderate asthma. No significant change was observed on the spontaneous recovery day except in FEV1. Dipyrone had a significant effect leading to an improved small airway function in asthmatic patients with moderate airway obstruction, confirming our recent in vitro findings.


  • Direct Medical Cost of Asthma in Ankara, Turkey

    by Gülfem E. Çelik, Sevim Bavbek, Gülden Paşaoğlu, Dilşad Mungan, Öznur Abadoğlu, Emel Harmancı, Zeynep Mısırlıgil

    Background: There has been no documented data regarding the cost of asthma in our country. Objective: In this 1-year prospective study, we aimed to determine the annual cost of asthma in Ankara, Turkey. Methods: Direct medical cost analysis was performed in 118 patients. Results: Mean annual direct medical costs of asthma were USD 1,465.7 ± 111.8 per capita. Medication cost comprised the majority (81%) of the total direct cost. Mean direct medical costs according to the stage of disease were USD 172.5 ± 51.7, 860.7 ± 70.2, 1,671.6 ± 141.8 and 3,491.9 ± 417.6 for stage 1 (n = 4), 2 (n = 54), 3 (n = 46) and 4 (n = 14) patients, respectively. Conclusions: In this first study to document the cost of asthma for our region, direct cost of asthma was found to be increased with the severity of the illness. Considering the fact that medication cost comprises the major fraction of the direct cost, cost-effectiveness trials to determine the effective treatment with optimal cost for different asthma stages should be the next step.


  • Clinical Features and Atopy Profile in Turkish Subjects with Analgesic Intolerance

    by Gülfem Çelik, Dilşad Mungan, Faruk Özer, Dane Ediger, Sevim Bavbek, Betül Sin, Yavuz S. Demirel, Zeynep Mısırlıgil

    The factors underlying analgesic intolerance (AI), particularly the role of ethnic characteristics, are readily not clear. In this trial, we aimed to assess the predictive features of AI in Turkish subjects. One hundred and ninety patients with AI were enrolled into the study conducted in our tertiary care clinic. The types of drug causing adverse reaction(s) and types of reaction(s) were recorded. The presence of atopy was assessed by skin prick tests. According to the results, the most frequently intolerated analgesic was acetyl salicylic acid (72.1%), followed by nonsteroidal anti-inflammatory drugs (68.4%) and paracetamol (15.8%). Urticaria/angioedema (52.6%) and asthmatic response (40.5%) were the most common reactions to analgesics. Compared with the general adult population of Turkey, the rate of atopy was found be higher in patients with AI and asthma (25% vs. 45%, p = 0.004) but comparable in patients with AI but no atopic disorder (25% vs. 29.2%, p> 0.05). In conclusion, subjects exhibiting intolerance to analgesics have particular features in our population; the presence of atopy in these subjects seems to be associated with the coexistent asthma rather than the drug allergy itself.


  • Risk Factors Determining Allergic Airway Diseases in Turkish Subjects

    by Gülfem Çelik, Betül Sin, Siddik Keskin, Dane Ediger, Sevim Bavbek, Dilşad Mungan, Faruk Özer, Yavuz S. Demirel, Fikret Gürbüz, Zeynep Mısırlıgil

    With regard to changes in life-style after the 1980s, the reflection of environmental factors on the evolution of allergic airway disease (AAD) has not yet been analyzed in Turkey. In this trial, we aimed to determine the factors related to AAD in Turkish subjects. Patients diagnosed as having asthma and/or rhinitis with positive skin prick tests (SPTs) were accepted as members of the "atopic group" (n = 235). Subjects demonstrated to have negative SPTs and no clinical evidence of any atopic disorder were accepted as members of the "nonatopic control group" (n = 84). Data obtained from a questionnaire applied cross-sectionally to the study groups were compared for risk factor analysis. According to the results of univariate analysis, nonatopic controls were found to have been born in villages more frequently than those in the atopic group (14.3% vs. 4.7%, p = 0.02). Atopic group members had lived in apartments during childhood more frequently than nonatopic controls (53.6% vs. 38%, p = 0.04). A topic group members, particularly the asthmatics, had lower sibship size (< or = 1 sibling) (41.3% vs. 16.7%, p = 0.0003) and nonatopic subjects had higher sibship size (> or = 3 siblings) (73.8% vs. 43.4%, p < 0.0001). The rate of maternal atopy was higher in the atopic group (24.7% vs. 9.5%, p = 0.02). Place of birth, sibship size, and atopic status of the mother, but not house type, were found to be significant in the multivariate analysis. As a conclusion, rural life-style seems to have a protective effect on the development of atopy in Turkey. On the contrary, factors directly or indirectly related to urban life-style during early childhood were found to be associated with the allergic airway diseases.


  • Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E2 on this release from peripheral blood leucocytes in aspirin‐induced asthmatic patients

    by G. Çelik, S. Bavbek, Z. Misirligil, M. Melli

    Background The decrease in prostaglandin E2 (PGE2) release due to aspirin (ASA)‐induced cyclooxygenase inhibition and the increment in cysteinyl leukotriene (Cys‐LT) release secondary to the removal of the inhibitory effect of PGE2 on Cys‐LT release have been suggested in the pathogenesis of aspirin‐induced asthma (AIA).Objective In this study, we aimed to investigate the in vitro release of Cys‐LT and to determine the effect of PGE2 on Cys‐LT release from peripheral blood leucocytes of patients with AIA after stimulation by ASA.Patients and methods Patients with AIA (n = 13), patients with ASA‐tolerant asthma (ATA) (n = 12) and healthy volunteers as controls (n = 13) were included to the study. ASA and PGE2 at three different concentrations were applied to the peripheral blood leucocytes of the study group, and Cys‐LT levels following stimulants were assessed by enzyme immunoassay method.Results There was no difference in baseline Cys‐LT levels between groups (AIA 353.4 ± 55.5 pg/mL, ATA 354.7 ± 40.3 pg/mL, and control group 368.5 ± 30.2 pg/mL; P > 0.05). Though not present in other groups, the Cys‐LT level of 453.6 ± 70.0 pg/mL following ASA stimulation was higher than baseline in patients with AIA (P = 0.04). When PGE2 was added to the ASA‐stimulated samples of patients with AIA, Cys‐LT levels were measured as 298.7 ± 78.6 pg/mL, 279.8 ± 79.9 pg/mL, and 243.4 ± 51.3 pg/mL at PGE2 10−7 m, 10−6 m and 10−5 m concentrations, respectively. These levels were lower than the ASA‐stimulated Cys‐LT values (P = 0.03, P = 0.01 and P = 0.01, respectively). The inhibitory effect of different PGE2 concentrations on Cys‐LT release was also present in patients with ATA and in controls.Conclusion The increase in Cys‐LT levels following ASA stimulation seems to be unique to AIA, which was not present in patients with ATA and in healthy controls. The inhibitory effect of PGE2 on stimulated Cys‐LT levels is another important finding to elucidate the role of PGE2 in the pathogenesis of AIA.


  • Formoterol and Salmeterol in Partially Reversible Chronic Obstructive Pulmonary Disease: A Crossover, Placebo-Controlled Comparison of Onset and Duration of Action

    by Gülfem Çelik, Oya Kayacan, Sumru Beder, Gülten Durmaz

    Background: In contrast to the well-known activity profile in asthma, the precise efficacy and optimum dose schedules of long-acting β2-agonists in chronic obstructive pulmonary disease (COPD) are not clear. Objective: In this study, we aimed to compare the onset and the duration of action of a single inhalation of formoterol and salmeterol in COPD patients having partially reversible airway obstruction. Methods: In a double-blind, randomized, crossover and placebo-controlled study design, the respiratory functions of 22 patients (mean age 57.3 ± 5.4 years) having mild to severe COPD (5 mild, 8 moderate and 9 severe) and partially reversible airway obstruction [mean baseline reversibility of forced expiratory volume in 1 s (FEV1) 19.3 ± 3.1%] were evaluated after inhalation of 12 μg formoterol and 50 μg salmeterol. Results: Regarding the onset of bronchodilator action, the mean absolute increase of 0.20 liters in FEV1 10 min after inhalation of formoterol was significantly higher than baseline and that of placebo (0.04 liters), whereas that of salmeterol (0.11 liters) did not reach statistical significance. At 20 min, both formoterol (0.25 liters) and salmeterol (0.20 liters) produced a significant increase in FEV1 compared with baseline and with that of placebo (0.04 liters). The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and –0.12 liters, respectively). Concerning the duration of action, the 12-hour values of both formoterol (0.25 liters) and salmeterol (0.22 liters) were significantly higher than that of placebo (–0.12 liters). The area under the curve values of FEV1 of formoterol (3.5 ± 1.3 l·h) and salmeterol (3.2 ± 1.2 l·h) averaged over 12 h were comparable and higher than placebo values (1.2 ± 0.5 l·h). After formoterol inhalation 2 patients experienced tremor and 1 had palpitation; 1 tremor and 1 headache attack were noted after salmeterol. For the pharmacologically predictable side effects, there was no difference between the drugs. Conclusions: In conclusion, this study revealed that a single dose of 12 μg formoterol and 50 μg salmeterol provided comparable bronchodilation within 12 h and had tolerable side effects in patients with mild to severe COPD having partially reversible airway obstruction.


    • 1 June 1999
      • Vol. 54  (3) , 212-6

    Distinctive features and long-term survival of reversible and chronic hypercapnic patients with COPD.

    by S Saryal, G Celik, G Karabiyikoğlu

    Hypercapnic respiratory failure due to chronic obstructive pulmonary disease (COPD) is an indicator of poor prognosis compared to that for normocapnic patients. On the other hand, there exist particular patients who are hypercapnic during an acute exacerbation of COPD but revert to normocapnia after adequate therapy. The aims of this study were: 1) to document the admission characteristics of such patients in terms of clinical and laboratory findings; and 2) to analyse the long-term course and survival of chronic and reversible hypercapnic and normocapnic patients. Fifty-six consecutive patients, admitted with an acute exacerbation of COPD, were enrolled and divided into three groups according to arterial carbon dioxide tension (Pa,CO2) at first admission: 22 chronic hypercapnic (group 1), 15 reversible hypercapnic (group 2) and 19 normocapnic (group 3) patients. Age, sex, smoking history, white blood cell count, serum sodium, potassium, urea and albumin levels and pulmonary function tests at first admission were similar in the three groups. The haematocrit level was significantly higher in group 1 compared with the other groups. Groups 1 and 2 had lower pH, arterial oxygen tension (Pa,O2) and arterial oxygen saturation (Sa,O2) and a higher Pa,CO2 than group 3. The Pa,CO2 was also higher in group 1 than in group 2. The presence of cor pulmonale was significantly higher in group 1 compared with groups 2 and 3 (81.8 versus 60 and 10.5%, respectively). During the follow-up period, a significant increase was observed in airway obstruction associated with progressive hypercapnia and hypoxaemia in chronic hypercapnic patients, and 12 of 15 (80%) reversible hypercapnic patients progressed to a chronic hypercapnic status. The survival analyses after 10 yrs of follow-up revealed comparable survival durations in chronic and reversible hypercapnic patients (median of 8.86 versus 9.52 yrs, p > 0.05). In conclusion, despite careful monitoring of particular characteristics in chronic and reversible hypercapnic patients at the time of admission, no long-term predictivity of these features for either the course of the disease or survival could be found.


  • The Prevalence of Allergic Diseases and Atopy in Ankara, Turkey: A Two-Step Population-Based Epidemiological Study

    by Gülfem Çelik, Dilşad Mungan, Sevim Bavbek, Betül Sin, Dane Ediger, Yavuz Demirel, Zeynep Misirlgil

    To assess the prevalence of allergic diseases and atopy in adults, a two-step population-based epidemiological study was undertaken in Ankara, the capital city of Turkey. In step 1, a screening questionnaire adapted from the European Community Respiratory Health Survey (ECRHS) was applied in a cross-sectional manner. In step 2, a nested case-controlled design study was conducted and subjects were evaluated in the clinical setting for history, physical examination, skin prick tests (SPTs), and serum total IgE and phadiotop measurements. According to the results, self-reported current asthma prevalence in step 1 was lower compared with that in step 2 (3% vs. 7%, p < 0.05). The prevalences of food and drug allergy were 6.2% and 3.9%, respectively, in step 1, but were not demonstrated in any of the subjects in step 2. The overall prevalence of atopy was 25% after step 2 evaluation. In conclusion, allergic disorders are not uncommon in our adult population; however, sole application of a screening questionnaire appeared to be ineffective in revealing the accurate figures of asthma, and food or drug allergy.


  • Local and Peripheral Plasma Endothelin-1 in Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease

    by Gülfem Çelik, Gülseren Karabiyikoglu

    Endothelin-1 (ET-1) has been described to have crucial effects in the initiation and evolution of pulmonary hypertension (PH) secondary to cardiac disorders. However, the precise role of ET-1 in PH induced by chronic obstructive pulmonary disease (COPD) is not yet clear. The objective of this cross-sectional study was to determine the local and peripheral plasma ET-1 profile of COPD patients with or without PH. Twenty-six COPD patients with clinical and/or laboratory findings suspicious of PH, and 20 healthy smoker volunteers constituted the study population. Patients were allocated to PH (n = 17) and non-PH (n = 9) groups according to their pulmonary artery pressures determined by right-heart catheterization. Plasma ET-1 samples, obtained from the main pulmonary artery (mixed venous blood) and peripheral blood (radial artery and brachial vein), were assessed by radioimmunoassay. Brachial vein ET-1 levels were within normal ranges in PH (2.7 ± 0.5 pg/ml) and non-PH (3.2 ± 0.7 pg/ml) COPD patients compared with that of the controls (4.4 ± 0.1 pg/ml). Likewise, radial artery ET-1 levels in PH (3.3 ± 0.7 pg/ml) and non-PH (2.9 ± 0.8 pg/ml) groups, and in controls (3.4 ± 1.1 pg/ml) were also comparable. The pulmonary artery ET-1 concentration of the PH group (13.6 ± 3.7 pg/ml) was higher than that of the non-PH group (2.2 ± 0.4 pg/ml) and that of the peripheral blood levels of controls. Elevated pulmonary artery ET-1 in the PH group was inversely correlated only with PaO2 levels. These results could be taken as an evidence of a local role of ET-1 in COPD-induced PH, but it remains to be clarified whether ET-1 is a marker or a mediator of PH in COPD.